: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease
May 23, 2025

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s DiseaseToulouse, May 23rd 2025 Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly

+ Read More

your CDMO Partner for Cell Therapy

Linkedin
Cell-Easy

4 Bis avenue Hubert Curien

31100 Toulouse,

FRANCE

Science-driven CDMO specialized in Cell Therapy, Cell-Easy offers customized process development, GMP manufacturing and analytical services for immune cells and adult stem cells in Immuno-oncology and Regenerative Medicine fields.

Keep in touch

Privacy Policy